Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Adult Drug Effective in Treating Psoriasis in Children


Related Encyclopedia
 border=
Acne
Alagille Syndrome
Appendicitis
Asthma in Children
More...

Related Animations
 border=
Dental Cavities
Psoriasis
More...

Related Healthscout Videos
 border=
Picture Perfect Smile
Space Age Dental Scan
Bioengineering versus Avian-Based HA?
Better Balance: It is Rocket Science
More...

Related Drug Information
 border=
Adderal XR
Concerta
Strattera
More...

Related News Articles
 border=
Nitric Oxide Monitoring of Little Benefit for Kids' Asthma
Parents Not Best Barometer of Kid's Eating, Exercise Habits
Childhood Leukemia Subtype Resists Treatment
You Look Familiar
More...


Page:  << Prev | 1 | 2 | 3 | Next >>

"This is the first trial that's been done in children and adolescents in this whole category of biologics for psoriasis," Paller said.

Etanercept is a tumor necrosis factor receptor (TNF). People with psoriasis have too much TNF, and entaercept reduces the amount of TNF. But, it can also lower the immune system's ability to fight infections.

To assess whether or not the drug was as safe and effective in children under 17 as it is in adults, Paller and her colleagues recruited 211 children and adolescents with moderate to severe psoriasis to participate in the trial.

Text Continues Below



Paller said the researchers chose etanercept, because it's already being used to treat children with juvenile rheumatoid arthritis and appears to be safe in that population.

The study volunteers, all between the ages of 4 and 17, were randomly assigned to receive 12 weeks of once-weekly injections of 0.8 milligrams (mg) of etanercept or a placebo. After the initial 12-week phase of the study, everyone was put on once-weekly etanercept for 24 weeks. Finally, at 36 weeks, 138 study volunteers were randomly chosen again to receive either etanercept or a placebo.

After 12 weeks, 57 percent of those on etanercept showed a 75 percent or greater improvement in their symptoms, compared with 11 percent on a placebo. During the 24 weeks when everyone received etanercept, 68 percent of those who had initially been on etanercept and 65 percent of those who started on a placebo showed a 75 percent or greater response.

During the second "randomized" portion of the trial, 42 percent of those placed on a placebo began having symptoms again.

Several children experienced infections while on etanercept, but all recovered without complications, according to the study.

"This is an incredible result," Paller said. "What's really exciting is we were worried because we were using a pretty low amount of etanercept. In adults who achieved the same blood levels of etanercept, there was a 30 to 34 percent response [of 75 percent or more]. Kids clearly are showing a better response than adults," she added.

Page:  << Prev | 1 | 2 | 3 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 1/16/2008

Related Links
 border=
From Healthscout's partner site on skin cancer, SkinCancerConnection.com
VIDEO: Shock treatment for melanoma successful
SYMPTOMS: Images and information on skin cancer symptoms
Sunburn First Aid - Tips for Preventing Sunburn





SOURCES: Amy Paller, M.D., chairwoman of dermatology, Feinberg School of Medicine, Northwestern University, and pediatric dermatologist, Children's Memorial Hospital, Chicago; Mark Lebwohl, M.D., chairman of the medical advisory board, National Psoriasis Foundation, and chairman, department of dermatology, Mt. Sinai School of Medicine, New York City; Jan. 17, 2008, New England Journal of Medicine


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map